External beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) are often used to supplement brachytherapy in patients with prostate cancer, but the clinical benefit of this approach is unclear. Merrick and colleagues have investigated this in their recent study....
Purpose The goal of this work was to investigate the oncological outcome of whole pelvis radiotherapy (wpRT) in pathologic pelvic lymph node-positive (pN1) prostate cancer (PCa), evaluate the location of relapse, and identify potential prognostic factors. Patients and methods All patients undergoing...
Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT...
OC-30 RESULTS OF I-125 STRANDS +- EBRT +-ADT IN LOCALIZED PROSTATE CANCER COMPARED TO KATTAN (2002) NOMOGRAM PREDICTIONdoi:10.1016/S0167-8140(12)71998-9J.ZimmermannP.ZimmermannC.MoustakiSDOSRadiotherapy & Oncology
PURPOSE/OBJECTIVE(S) :High dose rate brachytherapy HDR-BT boost with external beam radiotherapy (EBRT) and adjuvant Androgen Deprivation Therapy (ADT) is an effective treatment of localized prostate cancer (PCa). Ionizing radiation (IR) delivered by BT or by EBRT induce DNA damage leading to ...
To evaluate the efficacy and toxicity of external beam radiation therapy (EBRT) combined with androgen deprivation therapy (ADT) for Japanese high-risk pro...vekri
External beam radiotherapy (EBRT) with or without brachytherapy boost (BTB) has not been compared in prospective studies using guideline-recommended radiation dose and recommended androgen-deprivation therapy (ADT). In this multicenter retrospective analysis, we compared modern-day EBRT with BTB in ...
Optimal therapy for clinically node-positive, nonmetastatic (cN1) prostate cancer (PC) patients remains controversial, ranging from aggressive local therapy to palliative systematic therapy alone. Despite guideline support, it is unclear if a brachytherapy (BT) boost should be considered for cN1 ...
Freedom from biochemical failure (FFBF), cumulative incidence of androgen deprivation therapy use for biochemical or clinical failure post-treatment (CI of ADT) and metastasis-free survival (MFS) outcomes were measured. 518 patients met the inclusion criteria for this study. Median age at HDR-BT ...